Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 809Neoplasms, Plasma Cell 111Recurrence 109Immunoglobulin Light-chain Amyloidosis 50Neoplasms 33Amyloidosis 21Smoldering Multiple Myeloma 15Renal Insufficiency 13Paraproteinemias 12Lymphoma, Non-Hodgkin 12Hematologic Diseases 11Leukemia, Plasma Cell 10Lymphoma 9Plasmacytoma 8Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Disease 6Blood Protein Disorders 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Hodgkin Disease 5Neoplasm, Residual 4Nausea 4Myelodysplastic Syndromes 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Disease Progression 4Chromosome 17 deletion 4

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Dexamethasone × Plasma cell × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡